BridgeBio Oncology Therapeutics (BBOT) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BridgeBio Oncology Therapeutics (BBOT) has outperformed Upstream Bio (UPB) over the past year, losing 73.2% versus a loss of 76.3%. BridgeBio Oncology Therapeutics is the larger company by market cap ($265.4 million vs $257.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | UPB |
|---|---|---|
| Share price | $3.31 | $4.70 |
| Market cap | $265.38M | $257.42M |
| 1-day change | -3.22% | +3.30% |
| YTD return | -73.56% | -82.69% |
| 1-year return | -73.24% | -76.25% |
| EPS (TTM) | $-0.07 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $33.68 |
| 52-week low | $3.27 | $4.37 |
| Distance from 52-week high | -77.74% | -86.05% |
| Analyst consensus | none | none |
| Avg. price target upside | +641.69% | +562.55% |
| Average volume | 470.20K | 647.42K |
| Shares outstanding | 80.17M | 54.77M |
| Employees | 88 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
BBOT vs UPB FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Upstream Bio?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $265.38M compared with $257.42M for Upstream Bio (UPB).
Which stock has performed better over the past year, BBOT or UPB?
BBOT returned -73.24% over the past 12 months, compared with -76.25% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.